Clinical trial
A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With…
NCT00281697 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00281697 |
|---|---|
| Title | A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2) |
| Official title | A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Treated Metastatic Breast Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Placebo, Standard chemotherapy |
| Enrollment | 684 |
| Start date | Feb 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Sep 1, 2012 |
| First posted | Jan 25, 2006 |
| Last update posted | Jul 26, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: